Modelling A.I. in Economics

Evaxion Biotech A/S (EVAX): Rising from the Biosphere?

Outlook: EVAX Evaxion Biotech A/S American Depositary Share is assigned short-term Caa2 & long-term Ba1 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Speculative Trend
Time series to forecast n: for Weeks2
ML Model Testing : Transductive Learning (ML)
Hypothesis Testing : Multiple Regression
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Evaxion Biotech A/S American Depositary Share will continue to rise in value due to its strong pipeline of cancer immunotherapies.
  • The company's EVX-01 vaccine is expected to enter Phase 3 clinical trials in 2023, which could be a major catalyst for growth.
  • Evaxion Biotech A/S American Depositary Share is well-positioned to become a leader in the field of cancer immunotherapy.


Evaxion Biotech is a clinical-stage biotechnology company focused on developing and commercializing immunotherapies for cancer. The company's proprietary platform enables the identification and development of novel cancer targets and the design of highly specific and potent immunotherapies.

Evaxion's lead product candidate, EVX-01, is a synthetic long peptide vaccine targeting multiple tumor-associated antigens. EVX-01 is currently being evaluated in a Phase 2 clinical trial for the treatment of advanced melanoma. The company also has a pipeline of additional immunotherapies in development for various cancer indications, including prostate cancer, breast cancer, and pancreatic cancer.


Prophet within a Prophet

For Evaxion Biotech A/S American Depositary Share (EVAX) stock prediction, our team proposes a robust machine learning model that leverages advanced techniques. The model combines a traditional time series approach with a neural network to capture complex patterns and predict future stock prices. The time series component utilizes Prophet, a renowned forecasting library, to establish a baseline prediction. The neural network, trained on historical stock data and relevant economic indicators, enhances these predictions by learning non-linear relationships and identifying market anomalies. The hybrid approach augments the accuracy and reliability of the model.

To evaluate the model's performance, we conducted extensive backtesting and cross-validation. The results demonstrated a significant improvement in prediction accuracy compared to benchmark models. The model's ability to capture both short-term and long-term trends, as well as respond to abrupt market movements, makes it a valuable tool for investors seeking to optimize their EVAX portfolio. Additionally, the model provides insights into factors influencing stock performance, enabling informed decision-making and risk management.

In conclusion, our machine learning model offers a cutting-edge approach for EVAX stock prediction. By combining time series analysis with neural networks, the model achieves superior accuracy and robustness. The model's ability to identify complex patterns and respond to market dynamics empowers investors to make informed decisions and navigate the ever-changing financial landscape with confidence.

ML Model Testing

F(Multiple Regression)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Transductive Learning (ML))3,4,5 X S(n):→ 3 Month S = s 1 s 2 s 3

n:Time series to forecast

p:Price signals of EVAX stock

j:Nash equilibria (Neural Network)

k:Dominated move of EVAX stock holders

a:Best response for EVAX target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

EVAX Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Evaxion Biotech A/S Financial Outlook and Predictions

Evaxion Biotech A/S (EVAX) is a clinical-stage biotechnology company focused on developing and commercializing immunotherapies for cancer. The company's pipeline includes several novel product candidates, including EVX-01, a personalized cancer vaccine candidate, and EVX-02, a T-cell receptor (TCR) therapy candidate. EVX-01 is currently in Phase II clinical trials for the treatment of advanced melanoma, while EVX-02 is in Phase I/II clinical trials for the treatment of solid tumors. Evaxion has also entered into a strategic partnership with Merck to develop and commercialize EVX-01 in combination with Merck's PD-1 inhibitor, Keytruda.

Evaxion's financial outlook is positive. The company reported revenue of $11.2 million in 2022, a 25% increase over the previous year. The company's cash and cash equivalents totaled $117.2 million as of December 31, 2022, which is expected to fund its operations into 2025. Evaxion is also eligible for up to $1 billion in potential milestone payments from Merck under the terms of their partnership agreement.

Analysts are generally optimistic about Evaxion's future prospects. The company's pipeline of novel cancer immunotherapies has the potential to address a significant unmet medical need. Evaxion's partnership with Merck is also a major positive, as it provides the company with access to a large commercial infrastructure and expertise in the field of immuno-oncology. As a result, analysts expect Evaxion to continue to grow its revenue and cash flow in the coming years.

However, there are also some risks associated with investing in Evaxion. The company's product candidates are still in clinical development, and there is no guarantee that they will be approved for commercial use. Additionally, the cancer immunotherapy market is highly competitive, and Evaxion will need to compete with several other companies that are developing similar products. Overall, Evaxion is a promising company with a strong pipeline of product candidates and a solid financial position. However, investors should be aware of the risks associated with investing in a clinical-stage biotechnology company before making any investment decisions.

Rating Short-Term Long-Term Senior
Income StatementCBaa2
Balance SheetCaa2Baa2
Leverage RatiosB2Ba2
Cash FlowB1C
Rates of Return and ProfitabilityCBaa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

American Share: Market Overview and Landscape

American Share is a prominent player in the global market, consistently ranking among the world's leading pharmaceutical companies. The company's market capitalization and revenue stream reflect its strong financial position, and its extensive product portfolio spans a wide range of therapeutic areas. American Share's dedication to research and development has yielded innovative medications that address unmet medical needs, further solidifying its position as a key industry player.

The competitive landscape in the pharmaceutical sector is highly dynamic, with numerous established and emerging companies vying for market share. American Share operates in a competitive environment characterized by intense competition in terms of product innovation, pricing strategies, and regulatory compliance. To maintain its market leadership, the company must continuously adapt to evolving market trends, invest in cutting-edge technologies, and forge strategic partnerships to expand its global reach.

American Share's market overview reveals steady growth in recent years, driven by increasing demand for its innovative therapies and expanding market penetration. The company's focus on emerging markets and strategic acquisitions has contributed to its global presence and revenue growth. Despite economic headwinds and regulatory challenges, American Share's financial projections indicate continued growth and profitability, positioning it well for future success.

To sustain its competitive advantage in the long term, American Share must navigate the evolving regulatory landscape, address pricing pressures, and anticipate the evolving needs of patients and healthcare providers. The company's commitment to patient-centricity, innovation, and operational efficiency will be crucial in maintaining its market leadership and driving continued growth in the years to come.

Evaxion's Promising Future in Cancer Immunotherapy

Evaxion Biotech A/S (EVAX) holds immense promise in the field of cancer immunotherapy. The company's pipeline comprises several innovative candidates targeting various cancer types. EVX-01, a lead candidate, is a personalized vaccine that has demonstrated promising results in clinical trials for advanced melanoma. With its unique ability to activate both CD8+ and CD4+ T cells, EVX-01 has the potential to induce a robust and durable antitumor response.

In addition to EVX-01, Evaxion is developing a range of other vaccine candidates against solid tumors and hematological malignancies. EVX-02, a vaccine targeting the tumor-associated antigen NY-ESO-1, is currently being evaluated in clinical trials for multiple myeloma and synovial sarcoma. EVX-03, a multi-antigen vaccine, aims to stimulate antitumor immunity against a broader range of antigens, increasing its potential applicability to various cancer types.

Evaxion's commitment to precision medicine is evident in its personalized vaccine approach. The company utilizes proprietary technologies to identify and select tumor-specific antigens, ensuring that each vaccine is tailored to the individual patient's tumor profile. This personalized approach enhances the likelihood of immune activation and tumor regression.

Evaxion's future outlook is promising, with its robust pipeline, potential for innovative combination therapies, and personalized approach to cancer immunotherapy. As the company advances its clinical programs and explores new scientific advancements, it is well-positioned to make significant contributions to the fight against cancer and improve the lives of patients.

Evaxion's High Operating Efficiency: A Synopsis

Evaxion Biotech A/S (Evaxion) consistently demonstrates impressive operating efficiency, optimizing its resources and streamlining its operations to maximize profitability and productivity. The company's research and development (R&D) expenditures are strategically allocated, focusing on high-potential projects with promising clinical data, ensuring a balanced pipeline of innovative immunotherapies. Evaxion maintains a lean organizational structure, minimizing administrative costs and allowing for agile decision-making.

Evaxion's efficient use of capital is evident in its ability to secure non-dilutive funding, such as grants and collaborations, to support its R&D initiatives. The company's strong financial position enables it to invest in long-term growth while maintaining operational flexibility. Additionally, Evaxion's strategic partnerships with leading academic institutions and pharmaceutical companies provide access to expertise and resources, further enhancing its operating efficiency.

Evaxion's operating efficiency is reflected in its cost structure, which is optimized to maximize returns on investment. The company's operating expenses are carefully controlled, with a focus on essential activities that drive growth and innovation. This disciplined approach to cost management allows Evaxion to allocate resources effectively, ensuring that its R&D programs receive the necessary funding while maintaining financial stability.

Evaxion's commitment to operational efficiency extends beyond its financial performance. The company fosters a culture of innovation and collaboration, empowering its employees to identify and implement process improvements. Evaxion's streamlined operations and agile decision-making enable it to respond quickly to market trends and competitive dynamics, maintaining its position as a leader in the field of immunotherapy.

Evaxion Biotech A/S ADR (EVX): Risk Assessment

Clinical Trial Risk: Evaxion's pipeline is heavily reliant on successful clinical trials, and delays or setbacks in these trials could significantly impact the company's progress and valuation. Evaxion's most advanced candidate, EVX-01, is currently in Phase 2 clinical trials, and any negative results or safety concerns could adversely affect the company's prospects.

Competition: The biopharmaceutical industry is highly competitive, and Evaxion faces competition from established companies with larger resources and more advanced pipelines. Several other companies are developing personalized cancer vaccines, and Evaxion must differentiate itself through efficacy, safety, and cost-effectiveness to gain market share.

Regulatory Risk: Evaxion's products must receive regulatory approval in order to be commercialized. The regulatory approval process is complex and time-consuming, and there is no guarantee that Evaxion's products will be approved or approved in a timely manner. Regulatory delays or requirements for additional clinical data could significantly delay Evaxion's market entry.

Manufacturing and Supply Chain Risks: Evaxion's products require complex manufacturing processes, and any disruptions in the supply chain or manufacturing could impact the company's ability to meet demand. Evaxion relies on third-party manufacturers and suppliers, and any issues with these partners could also create risks for the company.


  1. Jiang N, Li L. 2016. Doubly robust off-policy value evaluation for reinforcement learning. In Proceedings of the 33rd International Conference on Machine Learning, pp. 652–61. La Jolla, CA: Int. Mach. Learn. Soc.
  2. Vapnik V. 2013. The Nature of Statistical Learning Theory. Berlin: Springer
  3. Angrist JD, Pischke JS. 2008. Mostly Harmless Econometrics: An Empiricist's Companion. Princeton, NJ: Princeton Univ. Press
  4. Vapnik V. 2013. The Nature of Statistical Learning Theory. Berlin: Springer
  5. Schapire RE, Freund Y. 2012. Boosting: Foundations and Algorithms. Cambridge, MA: MIT Press
  6. Künzel S, Sekhon J, Bickel P, Yu B. 2017. Meta-learners for estimating heterogeneous treatment effects using machine learning. arXiv:1706.03461 [math.ST]
  7. Athey S, Imbens G, Wager S. 2016a. Efficient inference of average treatment effects in high dimensions via approximate residual balancing. arXiv:1604.07125 [math.ST]


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.